查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1758765

全球液體切片檢查市場

Fluid Biopsy
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 282 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計到 2030 年全球液體切片檢查市場規模將達到 210 億美元

全球液體切片檢查市場規模預計在2024年為114億美元，到2030年將達到210億美元，在分析期間（2024-2030年）的複合年成長率為10.6%。作為本報告分析的細分市場之一，肺癌市場預計將以12.4%的複合年成長率成長，到分析期結束時達到82億美元。乳癌市場在分析期間內的複合年成長率預計為8.3%。

美國市場規模估計為 31 億美元，中國市場預計複合年成長率為 14.7%

美國液體切片檢查市場規模預計2024年達到31億美元。作為世界第二大經濟體，中國預計到2030年市場規模將達到44億美元，在2024-2030年的分析期間內，複合年成長率為14.7%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個市場的複合年成長率分別為7.5%和9.5%。在歐洲，預計德國市場的複合年成長率約為8.4%。

全球液體切片檢查市場－主要趨勢和促進因素摘要

為什麼液體切片切片檢查會成為癌症診斷領域的顛覆性力量？

液體切片檢查（又稱液態切片）正在改變癌症診斷和疾病監測，它提供了一種非侵入性的傳統組織切片檢查替代方法。液體切片檢查透過分析來自生物體液（主要是血液）的腫瘤衍生成分，例如循環腫瘤DNA (ctDNA)、循環性腫瘤細胞(CTC)、外泌體和微型RNA ，實現早期癌症檢測、即時疾病追蹤和治療反應評估。它無需手術取樣即可捕捉腫瘤異質性，這使得它在轉移性腫瘤和難以接近的腫瘤環境中尤其有價值。

這種方法因其在檢測微量殘存疾病(MRD)、識別可操作突變以及指南多種癌症（包括肺癌、乳癌、結直腸癌和前列腺癌等）的個性化治療決策方面的潛力，在腫瘤學領域獲得了廣泛關注。與可能受操作風險和空間限制的組織切片檢查不同，液體切片檢查允許在病程中反覆取樣。隨著精準醫療的不斷發展，液體切片檢查正成為動態腫瘤分析和治療調整的重要工具。

哪些技術進步正在擴大液體切片檢查的可能性？

分子生物學、基因組定序和數位PCR技術的進步極大地提高了液體切片檢查的準確性和臨床效用。次世代定序（NGS）平台如今能夠高靈敏度地檢測ctDNA中的低頻突變，從而能夠早期識別腫瘤相關的基因組變異。液滴數位PCR（ddPCR）和BEAMing（磁珠法、乳化法、擴增法、磁力法）正被用於定量突變，從而能夠縱向追蹤腫瘤的嚴重和治療反應。

基於微流體的平台和CTC富集技術正在提高從血液樣本中捕獲稀有細胞和顆粒的效率。同時，人工智慧主導的數據解讀工具正在促進複雜分子特徵的快速分析，以支援即時臨床決策。尿液、腦脊髓液和唾液等多種體液類型生物標記的多重分析和整合方面的進展，正在將液體切片檢查的應用範圍從腫瘤學擴展到產前篩檢、器官移植監測和感染疾病監測等其他領域。

哪些臨床/治療領域擴大採用液體切片檢查？

液體切片檢查主要用於腫瘤學，以支持早期癌症篩檢、伴隨診斷和抗藥性突變檢測。例如，在非小細胞肺癌 (NSCLC) 中，液體切片檢查通常用於檢測 EGFR 突變並指導標靶治療。乳癌和攝護腺癌也是重要的研究領域，在這些領域中，連續液體切片檢查有助於監測荷爾蒙受體狀態和轉移進展，而無需重複影像學檢查或手術。

除了固體癌外，骨髓惡性腫瘤也開始受益於基於ctDNA的微量殘存疾病檢測，尤其是在白血病和淋巴瘤。臨床試驗通常結合液體切片檢查終點來分層患者、評估藥物療效，並將分子反應與臨床結果關聯。同時，液體活體組織切片在免疫腫瘤學中的應用也在不斷擴展，研究人員正在使用液體切片檢查來評估腫瘤突變負荷(TMB)並預測對查核點抑制劑的療效。液體切片檢查的多功能性和擴充性使其在人群篩檢舉措和照護現場診斷框架中廣泛應用。

支持液體切片檢查市場成長的關鍵促進因素有哪些？

液體切片檢查市場的成長受到多種因素的共同驅動，這些因素根植於臨床效用、技術成熟度以及醫療保健系統的需求。主要促進因素是對非侵入性、患者友善診斷工具日益成長的需求，這些工具可以減少手術相關併發症並實現頻繁的疾病監測。這符合全球對個人化醫療、早期療育和基於結果的治療模式的青睞趨勢。

隨著低成本先進定序技術的出現，液體切片檢查正日益普及，臨床醫生和診斷實驗室都能夠輕鬆應用。全球癌症發生率的上升，加上對及時分子決策支援的需求，正加速其在臨床上的應用。基於液態切片的伴隨診斷已獲得監管機構的核准，主要市場也開始提供報銷支持，這進一步鞏固了液態切片在標準腫瘤學工作流程中的地位。此外，精準腫瘤學研究、生物製藥合作以及新興企業創新的強勁投資，正在催生一個充滿活力且競爭激烈的生態系統，不斷拓展液體切片檢查應用的前沿領域。這些因素共同作用，使液體切片檢查成為未來疾病檢測和個人化治療的顛覆性技術。

部分

適應症（肺癌、乳癌、結腸癌、其他適應症）；模式種（循環性腫瘤細胞、循環腫瘤DNA、遊離DNA）

受訪公司範例（總合42家公司）

  • Angle plc
  • Biocept, Inc.
  • Bio-Rad Laboratories, Inc.
  • Caris Life Sciences
  • CellMax Life
  • Cynvenio Biosystems, Inc.
  • Epigenomics AG
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd
  • Freenome Holdings, Inc.
  • GRAIL, Inc.
  • Guardant Health, Inc.
  • Helio Health
  • Illumina, Inc.
  • Inivata Ltd
  • Invitae Corporation
  • Lucence Diagnostics Pte Ltd
  • Menarini Silicon Biosystems
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • NeoGenomics Laboratories
  • QIAGEN NV
  • Resolution Bioscience（Agilent）
  • Sysmex Corporation
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.

人工智慧整合

我們正在利用可操作的專家內容和人工智慧工具來改變市場和競爭情報。

Global 特定產業SLM 的典型規範，而是建立了一個從全球專家收集的內容庫，其中包括視訊錄影、部落格、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地、進出口狀況（成品和原始OEM）預測其競爭態勢的變化。這種複雜且多面向的市場動態預計將以多種方式影響競爭對手，包括銷貨成本成本 (COGS) 上升、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東地區
  • 非洲

第4章 競賽

簡介目錄
Product Code: MCP36918

Global Fluid Biopsy Market to Reach US$21.0 Billion by 2030

The global market for Fluid Biopsy estimated at US$11.4 Billion in the year 2024, is expected to reach US$21.0 Billion by 2030, growing at a CAGR of 10.6% over the analysis period 2024-2030. Lung Cancer, one of the segments analyzed in the report, is expected to record a 12.4% CAGR and reach US$8.2 Billion by the end of the analysis period. Growth in the Breast Cancer segment is estimated at 8.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.1 Billion While China is Forecast to Grow at 14.7% CAGR

The Fluid Biopsy market in the U.S. is estimated at US$3.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.4 Billion by the year 2030 trailing a CAGR of 14.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.5% and 9.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.4% CAGR.

Global Fluid Biopsy Market - Key Trends & Drivers Summarized

Why Is Fluid Biopsy Emerging as a Disruptive Force in Cancer Diagnostics?

Fluid biopsy-also known as liquid biopsy-is transforming cancer diagnostics and disease monitoring by offering a non-invasive alternative to traditional tissue biopsies. By analyzing tumor-derived components such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, and microRNAs from biological fluids (mainly blood), fluid biopsy enables early cancer detection, real-time disease tracking, and therapeutic response assessment. Its ability to capture tumor heterogeneity without the need for surgical sampling is particularly valuable in metastatic and inaccessible tumor settings.

This approach is gaining prominence in oncology due to its potential for detecting minimal residual disease (MRD), identifying actionable mutations, and guiding personalized therapy decisions across various cancer types-particularly lung, breast, colorectal, and prostate cancers. Unlike tissue biopsies that may be limited by procedural risks and spatial constraints, fluid biopsy allows for repeatable sampling over the disease course. As precision medicine continues to evolve, fluid biopsy is becoming an essential tool for dynamic tumor profiling and treatment adjustment.

What Technological Innovations Are Expanding the Potential of Fluid Biopsies?

Technological advancements in molecular biology, genomic sequencing, and digital PCR have significantly expanded the accuracy and clinical utility of fluid biopsies. Next-generation sequencing (NGS) platforms can now detect low-frequency mutations in ctDNA with high sensitivity, enabling early identification of tumor-related genomic alterations. Droplet digital PCR (ddPCR) and BEAMing (Beads, Emulsion, Amplification, Magnetics) are being utilized for mutation quantification, allowing for longitudinal tracking of tumor burden and therapy response.

Microfluidics-based platforms and CTC enrichment technologies are improving the capture efficiency of rare cells and particles from blood samples. Simultaneously, AI-driven data interpretation tools are facilitating rapid analysis of complex molecular signatures, supporting real-time clinical decision-making. Advances in multiplexing and integration of biomarkers from multiple fluid types-including urine, cerebrospinal fluid, and saliva-are extending fluid biopsy’s applications beyond oncology into other domains such as prenatal screening, organ transplant monitoring, and infectious disease surveillance.

Which Clinical and Therapeutic Areas Are Accelerating Adoption of Fluid Biopsy?

Fluid biopsy is primarily utilized in oncology, where it supports early cancer screening, companion diagnostics, and resistance mutation detection. In non-small cell lung cancer (NSCLC), for example, fluid biopsy is routinely used to detect EGFR mutations and guide the use of targeted therapies. Breast and prostate cancers are also key areas where serial fluid biopsies help monitor hormone receptor status and metastatic progression without repeated imaging or surgery.

Beyond solid tumors, hematological malignancies are beginning to benefit from ctDNA-based minimal residual disease detection, particularly in leukemias and lymphomas. Clinical trials now commonly incorporate fluid biopsy endpoints to stratify patients, evaluate drug efficacy, and correlate molecular response with clinical outcomes. Meanwhile, its application in immuno-oncology is expanding as researchers use fluid biopsy to assess tumor mutational burden (TMB) and predict response to checkpoint inhibitors. The versatility and scalability of fluid biopsy are also enabling broader adoption in population screening initiatives and point-of-care diagnostic frameworks.

What Are the Main Drivers Supporting Growth in the Fluid Biopsy Market?

The growth in the fluid biopsy market is driven by several converging factors rooted in clinical utility, technological maturity, and healthcare system needs. A primary driver is the growing demand for non-invasive, patient-friendly diagnostic tools that reduce procedure-related complications and enable frequent disease monitoring. This aligns with global trends favoring personalized medicine, early intervention, and outcomes-based treatment models.

The increasing availability of advanced sequencing technologies at lower costs is making fluid biopsy more accessible to both clinicians and diagnostic laboratories. Rising cancer incidence worldwide, combined with the need for timely, molecular-level decision support, is accelerating clinical adoption. Regulatory approvals for liquid biopsy-based companion diagnostics and reimbursement support in key markets are further solidifying its role in standard oncology workflows. Additionally, robust investments in precision oncology research, biopharma collaborations, and startup innovation are fueling a dynamic and competitive ecosystem that continues to expand the frontiers of fluid biopsy applications. Collectively, these drivers position fluid biopsy as a transformative force in the future of disease detection and personalized treatment.

SCOPE OF STUDY:

The report analyzes the Fluid Biopsy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, Other Indications); Type (Circulating Tumor Cells, Circulating Tumor DNA, Cell-Free DNA)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Angle plc
  • Biocept, Inc.
  • Bio-Rad Laboratories, Inc.
  • Caris Life Sciences
  • CellMax Life
  • Cynvenio Biosystems, Inc.
  • Epigenomics AG
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd
  • Freenome Holdings, Inc.
  • GRAIL, Inc.
  • Guardant Health, Inc.
  • Helio Health
  • Illumina, Inc.
  • Inivata Ltd
  • Invitae Corporation
  • Lucence Diagnostics Pte Ltd
  • Menarini Silicon Biosystems
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • NeoGenomics Laboratories
  • QIAGEN N.V.
  • Resolution Bioscience (Agilent)
  • Sysmex Corporation
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Fluid Biopsy - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Cancer Throws the Spotlight on Non-Invasive Diagnostic Technologies
    • Growing Clinical Focus on Real-Time Tumor Monitoring Drives Demand for Liquid Biopsy Platforms
    • Technological Advancements in Circulating Biomarker Detection Accelerate Market Expansion
    • Expansion of Precision Medicine Programs Strengthens Business Case for Fluid Biopsy Applications
    • Integration of Multi-Omics Approaches Spurs Innovation in Personalized Cancer Diagnostics
    • Increase in Pharmaceutical R&D Pipelines Boosts Utility of Fluid Biopsy in Clinical Trials
    • Emergence of cfDNA and CTC-Based Panels Expands Diagnostic Utility Beyond Oncology
    • Surge in Patient Preference for Less Invasive Procedures Generates Growth Opportunities
    • AI-Powered Data Analysis Tools Improve Accuracy and Interpretation of Fluid Biopsy Results
    • Growth in Early Cancer Screening Initiatives Drives Adoption of Blood-Based Biopsy Platforms
    • Advances in Microfluidics and NGS Technologies Enhance Sensitivity of Fluid Biopsy Systems
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Fluid Biopsy Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Fluid Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Fluid Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Fluid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Colorectal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Circulating Tumor Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Circulating Tumor Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Circulating Tumor Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Circulating Tumor DNA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Circulating Tumor DNA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Circulating Tumor DNA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Cell-Free DNA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Cell-Free DNA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Cell-Free DNA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Fluid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • JAPAN
    • Fluid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • CHINA
    • Fluid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • EUROPE
    • Fluid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Fluid Biopsy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Fluid Biopsy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Fluid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • FRANCE
    • Fluid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • GERMANY
    • Fluid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Fluid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Fluid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Fluid Biopsy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Fluid Biopsy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Fluid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Fluid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • INDIA
    • Fluid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Fluid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Fluid Biopsy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Fluid Biopsy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Fluid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Fluid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Fluid Biopsy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Fluid Biopsy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Fluid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • AFRICA
    • Fluid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030

IV. COMPETITION